M-phase MELK activity is regulated by MPF and MAPK

CNRS UMR 6061 Génétique et Développement, Université de Rennes, Rennes, France.
Cell cycle (Georgetown, Tex.) (Impact Factor: 4.57). 05/2006; 5(8):883-9.
Source: PubMed


The protein kinase MELK is implicated in the control of cell proliferation, cell cycle and mRNA splicing. We previously showed that MELK activity is correlated with its phosphorylation level, is cell cycle dependent, and maximal during mitosis. Here we report on the identification of T414, T449, T451, T481 and S498 as residues phosphorylated in Xenopus MELK (xMELK) in M-phase egg extract. Phosphorylations of T449, T451, T481 are specifically detected during mitosis. Results obtained in vivo showed that MPF and MAPK pathways are involved in xMELK phosphorylation. In vitro, MPF and MAPK directly phosphorylate xMELK and MPF phosphorylates xMELK on T481. In addition, phosphorylation by MPF and MAPK enhances MELK activity in vitro. Taken together our results indicate that MELK phosphorylation by MPF and MAPK enhance its activity during M-phase.

Download full-text


Available from: Caroline Badouel, Dec 11, 2014
1 Follower
59 Reads
  • Source
    • "In human cells and Xenopus embryos, MELK is phosphorylated during mitosis, which correlates with the increase in its catalytic activity (Blot et al., 2002; Davezac et al., 2002). In xMELK, we have identified multiple sites phosphorylated specifically during mitosis (Badouel et al., 2006). The two major mitotic kinases, cyclin B-CDK1 complex and mitogen-activated protein kinase ERK2, participate in these phosphorylation events and enhance MELK activity in vitro. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Maternal Embryonic Leucine zipper Kinase (MELK) was recently shown to be involved in cell division of Xenopus embryo epithelial cells. The cytokinetic furrow of these cells ingresses asymmetrically and is developmentally regulated. Two subpopulations of xMELK, the mMELK (for "mitotic" xMELK) and iMELK ("interphase" xMELK), which differ in their spatial and temporal regulation, are detected in Xenopus embryo. How cells regulate these two xMELK populations is unknown. In this study we show that, in epithelial cells, xMELK is present at a higher concentration at the apical junctional complex, in contrast to mesenchyme-like cells, which have uniform distribution of cortical MELK. Interestingly, mMELK and iMELK also differ by their requirements towards cell-cell contacts to establish their proper cortical localization both in epithelial and mesenchyme-like cells. Receptor for Activated protein Kinase C (RACK1), which we identified as an xMELK partner, co-localizes with xMELK at the tight junction. Moreover, a truncated RACK1 construct interferes with iMELK localization at cell-cell contacts. Collectively, our results suggest that iMELK and RACK1 are present in the same complex and that RACK1 is involved in the specific recruitment of iMELK at the apical junctional complex in epithelial cells of Xenopus embryos.
    Biology Open 10/2013; 2(10):1037-48. DOI:10.1242/bio.20136080 · 2.42 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Le complexe passager joue un rôle clé en mitose: contrôlant à la fois la ségrégation des chromosomes, la tension du fuseau, l'entrée en anaphase et la cytodirèse. Le complexe est composé de quatre protéines: INCENP, la kinase Aurora B, Survivine et Boréaline. Sachant que la protéine Survivine est phosphorylée par Aurora B et qu'elle a un role pivot au sein du complexe, nous avons étudié un mutant mimant sa phosphorylation: Survivine T117E. La phosphorylation de Survivine est nécessaire à la transition Métaphase/ Anaphase. Le mutant Survivine T117E est faiblement lié aux centromères en métaphase et agit comme un dominant négatif de la cytodirèse, empêchant la séparation des deux cellules filles. Lors de la recherche d'inhibiteurs des Aurora kinases, nous avons identifié une nouvelle classe de molécules qui inhibent la phosphorylation de l'histone H3 et le point de contrôle du fuseau. Ces molécules préviennent la prolifération des cellules tumorales. Ces composés sont des outils intéressants pour étudier la fonction du complexe passager et représentent un nouveau motif moléculaire pour le développement de drogues anticancéreuses. Survivine et Aurora B kinase dont l'expression est restreinte à la mitose sont deux cibles pour de nouvelles thérapies anti-mitotiques.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: We have performed cDNA microarray analyses to identify gene expression differences between highly invasive glioblastoma multiforme (GBM) and typically benign pilocytic astrocytomas (PA). Despite the significant clinical and pathological differences between the 2 tumor types, only 63 genes were found to exhibit 2-fold or greater overexpression in GBM as compared to PA. Forty percent of these genes are related to the regulation of the cell cycle and mitosis. QT-PCR validation of 6 overexpressed genes: MELK, AUKB, ASPM, PRC1, IL13RA2 and KIAA0101 confirmed at least a 5-fold increase in the average expression levels in GBM. Maternal embryonic leucine zipper kinase (MELK) exhibited the most statistically significant difference. A more detailed investigation of MELK expression was undertaken to study its oncogenic relevance. In the examination of more than 100 tumors of the central nervous system, we found progressively higher expression of MELK with astrocytoma grade and a noteworthy uniformity of high level expression in GBM. Similar level of overexpression was also observed in medulloblastoma. We found neither gene promoter hypomethylation nor amplification to be a factor in MELK expression, but were able to demonstrate that MELK knockdown in malignant astrocytoma cell lines caused a reduction in proliferation and anchorage-independent growth in in vitro assays. Our results indicate that GBM and PA differ by the expression of surprisingly few genes. Among them, MELK correlated with malignancy grade in astrocytomas and represents a therapeutic target for the management of the most frequent brain tumors in adult and children.
    International Journal of Cancer 03/2008; 122(4):807-15. DOI:10.1002/ijc.23189 · 5.09 Impact Factor
Show more

Similar Publications